Journal article
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
MA Roberts, HL Pilmore, FL Ierino, SV Badve, A Cass, AX Garg, CM Hawley, NM Isbel, H Krum, EM Pascoe, AM Tonkin, LA Vergara, V Perkovic
Nephrology | WILEY | Published : 2015
DOI: 10.1111/nep.12362
Abstract
Aims The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a large-scale randomized controlled trial with clinical endpoints comparing the beta-blocking agent carvedilol with placebo in patients receiving dialysis. Methods The BLOCADE Feasibility Study is a randomized, double-blind, placebo-controlled, parallel group feasibility study comparing the beta-blocking agent carvedilol with placebo. Patients receiving dialysis for ≥3 months and who are aged ≥50 years, or who are ≥18 years and have diabetes or cardiovascular disease, were eligible. The primary outcome was the proportion of participants who complete a 6-week run-in p..
View full abstractRelated Projects (1)
Grants
Awarded by New Zealand Health Research Council Feasibility Study Grant
Awarded by National Health and Medical Research Council (NHMRC) Project Grant
Awarded by NHMRC Training Fellowship
Funding Acknowledgements
The BLOCADE Feasibility Study acknowledges the following funding sources: Don & Lorraine Jacquot Collaborative Research Initiative Grant (2008), the New Zealand Health Research Council Feasibility Study Grant (10-163), the National Health and Medical Research Council (NHMRC) Project Grant (1006171) and Pfizer CVL (2008). Roche Products, Pty Limited provided Dilatrend(R) at a discounted price. In addition, MAR was supported by an NHMRC Training Fellowship (628902).